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Abstract Poly(L-lactic acid) microspheres loaded with
holmium-166 acetylacetonate (
166Ho-PLLA-MS) are a
novel microdevice for intra-arterial radioembolization in
patients with unresectable liver malignancies. The neutron
activation in a nuclear reactor, in particular the gamma
heating, damages the
166Ho-PLLA-MS. The degree of
damage is dependent on the irradiation characteristics and
irradiation time in a particular reactor facility. The aim of
this study was to standardize and objectively validate the
activation procedure in a particular reactor. The methods
included light- and scanning electron microscopy (SEM),
particle size analysis, differential scanning calorimetry,
viscometry, thermal neutron flux measurements and energy
deposition calculations. Seven hours-neutron irradiation
results in sufficient specific activity of the
166Ho-PLLA-
MS while structural integrity is preserved. Neutron flux
measurements and energy deposition calculations are
required in the screening of other nuclear reactors. For the
evaluation of microsphere quality, light microscopy, SEM
and particle size analysis are appropriate techniques.
Keywords Holmium.Microspheres.Neutron irradiation.
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1 Introduction
The global incidence of hepatocellular carcinoma (HCC),
the most common type of primary liver cancer, is high
(>600,000 new cases per year) and still increasing (Gomaa
et al. 2008; Parkin et al. 2005). The only potentially
curative treatment option in HCC is surgical resection.
Unfortunately, most patients are presented with unresect-
able disease, and due to the lack of effective treatment
alternatives, HCC is the 3rd cause of cancer related death
(Parkin et al. 2005). The liver is also a very common organ
for other cancers to spread to. This is especially the case for
primary cancers of the gastrointestinal tract. Metastasis
confined to the liver very often occurs in colorectal cancer,
of which the global incidence is very high as well
(~1,000,000 new cases per year), particularly in the
Western World. Colorectal cancer ranks as the 3rd most
commonly diagnosed cancer type. The primary potentially
curative treatment for colorectal liver metastases is surgical
resection as well, yet only a minority of patients is eligible.
The overall prognosis of colorectal cancer is rather good
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in the liver are often unresectable, colorectal cancer is the
4th cause of cancer related death (Parkin et al. 2005).
Therefore, the need exists for novel treatment options for
patients with unresectable liver malignancies.
One emerging treatment option for patients with unre-
sectable liver tumors is intra-arterial microbrachytherapy
via radioactive microspheres, loaded with the high-energy
beta-emitting radioisotope yttrium-90 (
90Y: Eβmax=2.28 MeV ,
Iβ=99.9%; T1/2=64.1 h), instilled into the hepatic artery
(Gulec and Fong 2007; Vente et al. 2007). The
90Y
microspheres are deposited into the liver tumors in much
higher concentrations than into the non-tumorous liver as a
consequence of the difference in blood supply between the
normal liver and liver tumors. The normal liver is supplied by
both the hepatic artery and (mainly) the portal vein, whereas
liver tumors derive their blood uniquely from the hepatic
artery (Bierman et al. 1951).
Apart from these
90Y microspheres, holmium-166 loaded
poly(L-lactic acid) microspheres (
166Ho-PLLA-MS) are
being developed for clinical application (Zielhuis et al.
2006a; Nijsen et al. 2001). Whereas
90Y is a pure beta
emitter,
166Ho is a combined beta-gamma emitter (
166Ho:
Eβmax=1.77 and 1.85 MeV, Iβ=48.7% and 50.0%, respec-
tively; Eγ=81 keV, Iγ=6.7%; T1/2=26.8 h) and highly
paramagnetic as well. It therefore offers medical imaging
possibilities, through both single photon emission com-
puted tomography (SPECT) and magnetic resonance
imaging (MRI). Quantitative analysis of the SPECT scans
and the MRI scans has been demonstrated feasible (De Wit
et al. 2006; Nijsen et al. 2004; Seppenwoolde et al. 2004).
165Ho-PLLA-MS are prepared through a straight-forward
solvent evaporation method under Good Manufacturing
Practice (GMP) conditions and are subsequently neutron
activated in a nuclear reactor (Zielhuis et al. 2006a).
Extensive animal studies have been conducted in which it
was demonstrated that the toxicity profile of this micro-
device is acceptable (Vente et al. 2008; Zielhuis et al.
2007). Also, the pharmaceutical quality has been investi-
gated and found satisfactory (Zielhuis et al. 2006b; Zielhuis
et al. 2006c).
Another issue to be addressed was assessment of the
effects of the neutron irradiation on the microspheres
integrity. Especially the accompanying decomposition
damage caused by gamma photons and fast neutrons, and
possibly by the thermal neutron capture side reactions,
needs to be investigated (Yamaguchi and Waker 2007;
Nijsen et al. 2002; Lin and Yeh 1966). Gamma irradiation
is accompanied by both heating resulting from absorption
of gamma-photon energy and by the formation of free
radicals (Mader et al. 1996). The degree of damage that is
inflicted upon the organic PLLA matrix is consequently
dependent on the irradiation characteristics and irradiation
time in a particular reactor facility. It is paramount to know
exactly how long a typical patient dosage of
165Ho-PLLA-
MS (600 mg, 7.5–15 GBq) can be irradiated while remaining
sufficiently intact for treatment of patients. In order to have
sufficient time for transportation of the
166Ho-PLLA-MS
from the reactor to the hospital, the microspheres must be
neutron irradiated for a certain period of time. The minimum
irradiation time is therefore dependent on logistics and the
required amount of radioactivity to be instilled, consequently
the thermal neutron flux. Conversely, the maximum irradia-
tion time is set by the extent of irradiation damage that
occurs. The aim of this research was to standardize and
objectively validate the activation procedure in a particular
reactor facility. Therefore, the maximum irradiation time of
the
165Ho-PLLA-MS in a particular reactor was determined,
and techniques that are applicable for routine quality control
testing were defined. Methods used include photon and
neutron energy deposition calculations, measurement of the
thermal neutron flux, light microscopy, scanning electron
microscopy, particle size analysis, molecular weight assess-
ment using viscometry, and thermal analysis through differ-
ential scanning calorimetry.
2 Materials and methods
2.1 Aim and study design
1. To assess the maximum irradiation time, samples of
microspheres of 600 mg (typical patient dosage)
consisting of
165Ho-PLLA-MS or PLLA-MS were
neutron-irradiated for 0, 2, 4, 6, 7, 8, or 10 h;
2. To assess whether differences in microsphere character-
istics are observed, when neutron irradiation is carried
out in different time slots of the reactor cycle, 600 mg
samples consisting of
165Ho-PLLA-MS were neutron-
irradiated for 6 or 7 h, at the first section, half-way, and
at the last section of the reactor cycle. The variation in
microsphere quality within a week was investigated as
well in 6-h irradiated
166Ho-PLLA-MS (600 mg);
3. To assess whether self-shielding is a significant factor
in the neutron activation, the generated amount of
radioactivity was measured in samples of 50, 100, 200,
400, 800, and 1,000 mg of
166Ho-PLLA-MS after
neutron irradiation for 60 min.
2.2 Preparation of
165Ho-PLLA-MS and of PLLA-MS
The preparation of GMP-grade
165Ho-PLLA-MS has been
described in detail in a previous paper (Zielhuis et al.
2006a). In brief, holmium acetylacetonate (HoAcAc) and
PLLAwere dissolved in chloroform. This solution was sub-
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alcohol and, with the evaporation of the solvent, micro-
spheres were formed. The microspheres were collected
and fractionated according to size using stainless steel
sieves. Except for deletion of the HoAcAc, the PLLA-
MS were produced in the same manner. The micro-
spheres were collected and packed in high-density
polyethylene (HDPE) vials (type A; Posthumus Plastics,
Beverwijk, The Netherlands).
2.3 Neutron irradiation procedure and neutron
flux measurements
Neutron flux monitors were placed on both ends of the vials
packing the
165Ho-PLLA-MS or PLLA-MS. These neutron
flux monitors were prepared from a certified chromium
standard solution (NIST 3112a) and consisted of chromium
(0.52±0.03 mg) inside smaller HDPE vials (type V)
(Koster-Ammerlaan et al. 2008). The vials were then
wrapped in thin poly-ethylene foil and placed in a HDPE
‘rabbit’-irradiation container (type XY) (Fig. 1(a)). The
samples were irradiated in a pneumatic rabbit system
facility of the nuclear reactor of the Delft University of
Technology (Delft, The Netherlands) with a nominal
thermal neutron flux of 5×10
16 m
−2 s
−1. The
166Ho-
PLLA-MS samples were allowed to decay for between 4
and 8 weeks before analysis of the samples.
The amount of radioactivity (
51Cr) in the flux monitors
was measured through gamma-ray spectrometry, using a
germanium detector and a 92X-II spectrum analyzer which
was linked to a PC equipped with GammaVision®-32
software, version 5.0 (EG & G ORTEC, Oak Ridge, TN,
USA). Subsequently, the actual thermal neutron flux to
which the flux monitors had been exposed was calculated
using the following formula:
ϕ ¼
l   A320   mCr
N   seff   m   "   q   g   1   e l tIRR ðÞ   e l tWT 1   e l tCT ðÞ
m 2   s 1 
where
’ is the thermal neutron flux (m
−2 s
−1)
λ is the decay constant (ln2/T1/2)o f
51Cr :
2.896×10
−7 s
−1
A320 is the 320 keV gamma peak area
mCr is the average atomic mass of chromium :
51.9961 g mol
−1
N is the number of nuclei/mol (equal to Avogadro’s
number) : 6.022×10
23
σeff is the effective activation cross section of
50Cr :
1.53×10
−27 m
2
m is the weight of chromium in the vial (g)
ε is the counting efficiency at 320 keV (cps/dps)
θ is the isotopic abundance of
50Cr
(ratio
50Cr/(
50Cr+
52Cr)) : 4.35×10
−2
γ is the abundance of the 320 keV gamma photon :
9.83×10
−2
tIRR is the neutron irradiation time (s)
tWT is the waiting time between neutron activation
and spectrometry measurement (s)
tCT is the spectrometry measurement time (s)
Since the samples were located in the bottom half of the
vials, the effective neutron flux to which a sample is
Fig. 1 (a) Schematic represen-
tation of the HDPE ‘rabbit’ type
irradiation container (1) con-
taining the neutron flux moni-
tors (2)o ntop and bottom of the
vial that contains a sample of
165Ho-PLLA-MS or PLLA-MS
(3). The flux monitors and the
vial containing the sample are
wrapped in poly-ethylene foil
(4); (b) schematic representation
of the pneumatic rabbit system
(1) with the ‘rabbit’ at the distal
end of the system (2), next to the
reactor core of the Delft reactor,
which is composed of fuel rods
(U3Si2-Al) (3), borium-carbide
control rods, 73.3% removed
(4), and beryllium reflector
elements (5)
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follows:
ϕeff ¼ 1=3   ϕmonitor 1

þ 2=3   ϕmonitor 2

m 2 s 1 ½ 
where
’eff is the effective neutron flux
ϕmonitor1 is the neutron flux measured by the monitor
placed on top of the vial
ϕmonitor2 is the neutron flux measured by the monitor
placed on the bottom of the vial
2.4 Energy deposition calculations
Energy spectra and energy depositions of neutrons and
photons in the irradiation facility were calculated using the
stochastic transport Monte Carlo method based code
MCNP5 (X-5 Monte Carlo Team 2003). The code can be
used in several transport modes: neutron only, photon only,
or combined neutron/photon transport where the photons
are produced by neutron interactions. In the calculations
described here, the combined neutron/photon mode was
used. The neutron energy regime was from 10
−11 to
20 MeV for all isotopes, and the photon energy regime
was from 1 keV to 100 GeV.
The model describes the fuel assemblies in the Delft
reactor by individual fuel plates and uses 15 axial regions
along the height of the fuel. Each movable beryllium
reflector element was modeled separately. All the existing
beam tubes and irradiation facilities near the core were
represented in the model. The material composition of the
fuel was given per fuel assembly and per axial region. The
burn-up dependent fuel composition was determined
separately. The material composition was determined for
three cases with full xenon equilibrium:
1. Begin of cycle, after 12 megawatt-days (MWD) at full
power, with the control rods at 73.30% removed
(Fig. 1(b));
2. Half-way of cycle, after 68 MWD of full power, with
the control rods at 81.30% removed;
3. End of cycle, after 130 MWD at full power, with the
control rods at 97.03% removed.
The depletion of beryllium and the photo-neutron
production in beryllium were neglected. For the calcula-
tions the ENDF/B-VI data library was used as distributed
with the MCNP5 package. The model has been validated
on a recent Delft reactor configuration (2008) by comparing
the reactivity and the measured axial distribution of
59Co
(n,γ)
60Co reaction rates. The average value of this Co
activation measurement was used for power normalization,
the ratio of the total power to fission power was assumed to
be constant during the whole cycle. The aluminum tube of
the pneumatic rabbit system and the HDPE rabbit vial were
included in the calculations.
2.5 Particle size distribution, light microscopy and scanning
electron microscopy (SEM)
The particle size distributions (volume percentage) of the
non-irradiated samples (the control samples:
165Ho-PLLA-
MS and PLLA-MS) and the irradiated samples (
166Ho-
PLLA-MS and PLLA-MS) were determined using a
Coulter Counter Multisizer 3 apparatus (Beckman Coulter
Nederland, Mijdrecht, The Netherlands), equipped with a
100-μm aperture tube. The preset quality criteria were set at
minimally 95 vol.% between 15–60 μm, and 92 vol.%
between 20–50 μm. Microsphere morphology, i.e. the extent
ofdamage,was evaluatedusinglightmicroscopy.Thesurface
morphology was investigated by SEM using a Phenom®
electron microscope (FEI Electron Optics, Eindhoven, The
Netherlands). Samples were mounted on aluminum stubs and
sputter-coated with a Pt layer of 6 nm.
2.6 Modulated differential scanning calorimetry (MDSC)
Thermal analysis was performed using a DSC Q1000 (TA
Instruments Inc., New Castle, DE, USA). Samples of 6 mg
of
165Ho-PLLA-MS,
166Ho-PLLA-MS, and non-irradiated
and irradiated PLLA-MS were transferred into aluminum
pans which were then hermetically sealed. The samples
were heated from 20°C to 220°C at a rate of 2°C min
−1.
The measurements were analyzed using Universal Analysis
2000 software (version 3.9A; TA Instruments Inc., New
Castle, DE, USA).
2.7 Viscometry
The molecular weight was determined in the Ho-PLLA-MS
samples (0, 2, 4, 6, 8, 10 h irradiated), PLLA-MS samples
(0, 2, 4, 6, 7, 8, 10 h irradiated), and non-irradiated PLLA
standards (obtained from PURAC biochem B.V., Gorinchem,
The Netherlands) using dilute-solution viscometry. The
samples were dissolved in chloroform, and the measurements
were conducted at 25°C, using a Ubbelohde capillary
viscometer, as described in the literature (Omelczuk and
McGinity 1992).
2.8 Sterility of the
166Ho-PLLA-MS
To test the sterility of the microspheres, samples of 450 mg
of
165Ho-PLLA-MS, spiked with Bacillus pumilis spores as
abiologicalindicator,wereneutronirradiatedfor6h.Then,the
samples were tested for bacterial contamination by a certified
company (Bactimm B.V., Nijmegen, The Netherlands).
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3.1 Particle size distribution, light microscopy and scanning
electron microscopy (SEM)
Particle size analysis was performed on all samples (Fig. 2).
For detailed information on microsphere morphology, light
microscopy and SEM were employed (Figs. 3 and 4).
The particle size analyses of the
166Ho-PLLA-MS
showed that the required size distribution was guaranteed
up to neutron irradiation for 7 h (Fig. 2(a)). Both light
microscopic and SEM analysis showed that differences in
morphology were hardly detectable between samples
irradiated for 0, 2, and 4 h, with microspheres of these
samples all exhibiting a smooth, intact surface (Figs. 3(a–c)
and 4(a–c)). Although the surface of 6- and 7-h irradiated
166Ho-PLLA-MS displayed some damage, the morphology
of the microspheres was quite similar to that of the non-
irradiated samples (Figs. 3(d-e) and 4(d-e)). Microsphere
quality clearly decreased when exposed for a 8-h irradiation
period as small dents on the surface and a lot of fragments
were visible (Figs. 3(f) and 4(f)). In addition, the particle
size distribution was insufficient (Fig. 2(a)). Light micros-
copy and SEM of the 10-h irradiated
166Ho-PLLA-MS
revealed extensively damaged microspheres, only barely
spherical in shape (Figs. 3(g) and 4(g)). Particle size
analyses of these samples proved impossible due to
blockage of the apparatus’ probe aperture as a consequence
of the formation of particle agglomerates.
To assess the possible effects on microsphere quality
after neutron irradiation in different slots of the reactor
cycle,
165Ho-PLLA-MS were irradiated for 6 or 7 h in the
first, in the middle, and in the last section of the reactor
cycle. These samples all met the preset particle size criteria
(Fig. 5). The nuclear reactor explored in this study is a
research reactor which is started up each Monday and
shut off each Friday. Samples of
165Ho-PLLA-MS were
irradiated on Tuesdays, Wednesdays and Thursdays. No
differences in quality were observed; they all met the
required specifications.
For the PLLA-MS, particle size distribution was slightly
better than for the
166Ho-PLLA-MS (Fig. 2); the desired
size distribution was maintained after 8 h of neutron
irradiation. The PLLA-MS samples that were irradiated 0,
2, 4, and 6 h all remained completely spherical with an
intact surface as observed by light microscopy and SEM
(Figs. 3(h–k) and 4(h–k)). However, careful examination of
the light micrographs and (especially) SEM images of the
Fig. 2 (a) Mean particle size (± SD) of the Ho-PLLA-MS, neutron-
irradiated for 0, 2, 4, 6, 7, or 8 h; (b) mean particle size (± SD) of the
PLLA-MS, neutron-irradiated for 0, 2, 4, 6, 7, or 8 h (diamond 15–
60 μm; square 20–50 μm)
Fig. 3 (a–g) Light micrographs of Ho-PLLA-MS, neutron-irradiated
for 0, 2, 4, 6, 7, 8, or 10 h. In samples irradiated up to 7 h damage is
absent or minor (a–e). The damage observed in the 8-h irradiated
microspheres and in particular the 10-h irradiated microspheres is
characterized by crumbles and breaking (f–g); (h–n) light micrographs
of PLLA-MS, neutron-irradiated for 0, 2, 4, 6, 7, 8, or 10 h. In
samples irradiated up to 7 h damage is again absent or minor (h–l).
The 8-h irradiated microspheres reveal signs of melting, whereas in
the 10-h irradiated samples most microspheres have melted and only
sporadically some remnants of microspheres can be seen (m–n)
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had partially liquefied (Fig. 4(l)). This ‘melting’ was more
prominently visible on SEM images of the 8-h irradiated
PLLA-MS samples which occasionally showed that micro-
spheres had started to fuse (Fig. 4(m)). Ten-hour irradiation
yielded PLLA-MS which had been destroyed (Figs. 3(n)
and 4(n)). Particle size measurements of the latter samples
were impossible since they had basically been turned into a
solitary piece of an adhesive substance. In contrast to the
light micrograph where a few sphere-like structures were
still detectable, no spherical shape was found using SEM,
which may be due to sample preparation for SEM.
3.2 Energy deposition and neutron flux
Irradiation induced damage as a consequence of energy
deposition can be a problem in the production of
166Ho-
PLLA-MS. Therefore, energy deposition was calculated for
both neutrons and photons. The calculated total energy
deposition showed a small decrease during the reactor cycle
(Table 1). More than 93% of the total energy deposition
came from the photons. This is in accordance with previous
experimental findings which indicated that damage to the
166Ho-PLLA-MS is due mainly to gamma radiation
(Zielhuis et al. 2006c).
Like the ‘gamma heating’ the thermal neutron flux
measurements showed a slight decrease during the reactor
cycle (Fig. 6). The thermal neutron flux measured using Cr
monitors on top of the vials was 6.8% higher than measured
by the monitors on the vial bottoms (5.21±0.24 and 4.88±
0.28×10
16 m
−2 s
−1 (mean±SD), respectively). The effective
thermal neutron flux was 4.99±0.23×10
16 m
−2 s
−1 (mean±
SD). Without any correction for the variation of flux during
the reactor cycle the above would implicate that for a
requested patient dosage of 7.5 GBq
166Ho the actually
produced amount of radioactivity may vary between 6.8
and 8.2 GBq in 95% of cases. The consequence would be
that a liver absorbed dose intended to be 80 Gy would vary
between 73 and 87 Gy. This variation is accepted common
practice in nuclear medicine.
To identify whether facilities in other nuclear reactors
could be used for routine production of
166Ho-PLLA-MS,
Fig. 4 (a–g) Scanning electron micrographs of Ho-PLLA-MS,
neutron-irradiated for 0, 2, 4, 6, 7, 8, or 10 h. In samples irradiated
up to 7 h damage is absent or minor (a–e). On the dented surface of
the 8-h irradiated microspheres small microsphere fragments are seen
(f). Disintegration has progressed in the 10-h irradiated microspheres
with many microspheres actually having been broken into several
large chunks, and many smaller fragments visible as well (g); (h–n)
scanning electron micrographs of PLLA-MS, neutron-irradiated for 0,
2, 4, 6, 7, 8, or 10 h. In samples irradiated up to 6 h damage is absent
(h–k). In the 7-h irradiated samples a tendency to interfusion is
observed (l). Microsphere fusion is more frequently seen in the 8-h-
irradiated samples (m). In the 10-h irradiated samples microspheres
had completely melted, and no identifiable remnants of microspheres
were found (n)
Fig. 5 Mean particle size (± SD) of duplo samples of
166Ho-PLLA-
MS neutron-irradiated for 6 or 7 h at the first section, half-way, and at
the last section of the reactor cycle. Particle size was invariably within
the required specifications during the different time slots of the reactor
cycle (diamond 15–60 μm, 6 h; square 20–50 μm, 6 h; triangle 15–
60 μm, 7 h; multiplication symbol 20–50 μm, 7 h)
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photons, can be calculated and related to the thermal
neutron flux.
3.3 Linearity of the activated fraction
In order to determine whether self-shielding occurs, i.e. to
assess the relation between the amount of microspheres
irradiated and amount of radioactivity produced, ascending
amounts of
165Ho-PLLA-MS (50-1,000 mg) were irradiated
for 60 min. The specific activity (MBq/mg) was found to be
linearly related to the amount of microspheres (Fig. 7).
Coefficient of variance was only 2.6% (4.53±0.12 MBq/mg).
Neutron irradiation time does therefore not need to be adjusted
for different amounts of
165Ho-PLLA-MS.
3.4 Modulated differential scanning calorimetry
Both PLLA-MS and Ho-PLLA-MS, neutron irradiated for
0, 2, 4, 6, 7, 8, or 10 h, were analyzed by MDSC (Table 2).
Irradiation of PLLA-MS resulted in a decrease in melting
temperature (Tm) and decreased enthalpy of fusion (ΔHm)
with increasing irradiation time, indicating impairment of
the crystalline phase of the PLLA matrix inflicted by the
neutron irradiation. The Tm of non-irradiated PLLA-MS
was 179±0°C and decreased to 113±5°C for 6 h irradiated
samples. The ΔHm for fully crystalline monodisperse lactic
acid oligomers amounted to 93 J/g (De Jong et al. 1998).
The ΔHm for non-irradiated PLLA-MS was 57±6 J/g, and
decreased to 14±12 J/g after 6 h irradiation signifying that
crystallinity decreased by roughly 75%. After 7 h of neutron
irradiation and longer no melting peak in the DSC
thermogram was observed, indicating a complete loss of
crystallinity. The glass transition temperature (Tg) decreased
from 68°C to around 50°C after irradiation, and was non-
detectable after irradiation for 7 h and longer, which is
consistent with previously reported findings (Zielhuis et al.
2006c). These findings indicate that after irradiation of 7 h
structural changes of the polymer matrix occurred. This is
consistent with light microscopy and SEM analysis which
revealed the onset of surface changes at 7 h irradiation
(Fig. 4(l)).
165Ho-PLLA-MS showed a lower Tm and ΔHm
compared to non-irradiated PLLA-MS (148±5°C and 9±
4 J/g vs. 179±0°C and 57±6 J/g). This is in accordance
with previously reported findings and was ascribed to
interaction of the carbonyl groups of PLLA with the
holmium ion of the HoAcAc complex (Nijsen et al.
2002). After neutron irradiation of 2 h and longer no
melting transitions were observed in the
166Ho-PLLA-MS
thermographs, indicating absence of crystallinity. Glass
transition was present in the thermographs of the non-
Table 1 Energy depositions delivered on microspheres during
neutron irradiation
Reactor cycle time slot Energy deposition (10
13MeV/g h)
Neutrons
Begin 7.63±0.48
Mid 7.34±0.45
End 7.73±0.52
Photons
Begin 112.0±4.7
Mid 111.4±6.8
End 106.2±5.0
Neutrons + photons
Begin 119.7±5.2
Mid 118.7±7.0
End 113.9±5.5
Values are presented as mean±SD
Fig. 6 Effective thermal
neutron flux measurements at
the first section, middle-section,
and at the last section of the
reactor cycle (mean± SD,
n=12/section). A slight decline
in flux is observed
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as in the PLLA-MS samples glass transition was absent
after irradiation for 7 h and longer.
3.5 Viscometry
The molecular weight of PLLA-MS, neutron-irradiated for
0, 2, 4, 6, 7, 8, or 10 h, and Ho-PLLA-MS, irradiated for 0,
2, 4, or 6 h, was determined using dilute-solution
viscometry.
166Ho-PLLA-MS irradiated for 7, 8, or 10 h
were not included in this analysis because these samples
only partially dissolved in chloroform. A major difference
in molecular weight was observed between the non-
irradiated PLLA-MS and
165Ho-PLLA-MS. The measured
molecular weight of the PLLA in the
165Ho-PLLA-MS was
less than 40% that of the PLLA in the PLLA-MS. This
apparent lower molecular weight of the PLLA is most
likely due to the above mentioned interaction between
PLLA and HoAcAc and is in agreement with previously
published results on gel permeation chromatography anal-
ysis of PLLA-MS and Ho-PLLA-MS samples (Nijsen et al.
2002). After 2 h of irradiation the molecular weight in the
samples of both categories had already decreased strongly
(approximately 70%), as a consequence of radiation-
induced chain scissions. After 6 h of irradiation and longer
the molecular weight had decreased by over 90%. In spite
of this dramatic loss of PLLA chain length, the structural
integrity was guaranteed up to 7 h (see Section 3.1). It was
found in previous studies that providing the microspheres
had remained intact, a decrease in molecular weight is not
associated with a clinically relevant release of radioactivity
(<1%) (Zielhuis et al. 2006b; Nijsen et al. 2002;Van Es et
al. 2001).
3.6 Sterility of the
166Ho-PLLA-MS
After neutron irradiation, samples spiked with spores of
B. pumilis were tested for viable bacteria. Colony forming
units were detected only in the spiked, non-irradiated
sample. The finding that no viable bacteria were present
in the irradiated samples spiked with spores of B. pumilis
was expected since the D-value (90% kill value) of B.
pumilis spores is <2 kGy (Prince 1978) and the gamma
dose delivered on the sample was over 30 times higher than
the dose used in routine gamma-radiation sterilization
(840 kGy h
−1 and 25 kGy (minimum absorbed dose
(European Directorate for the Quality of Medicines &
HealthCare 2008), respectively). Since the samples had
been irradiated for 6 h the delivered gamma dose was in
excess of 5,000 kGy.
Irradiation time (h) Sample description Tg (°C) Tc (°C) ΔHc (J/g) Tm (°C) ΔHm (J/g)
0 PLLA-MS 68±3 152±1 5±0 179±0 57±6
2 PLLA-MS 50±2 80±1 28±1 150±1 40±2
4 PLLA-MS 43±8 nd nd 131±1 25±5
6 PLLA-MS 54±1 nd nd 113±5 14±12
7 PLLA-MS nd nd nd nd nd
8 PLLA-MS nd nd nd nd nd
10 PLLA-MS nd nd nd nd nd
0 Ho-PLLA-MS 65±2 123±14 9±6 148±5 9±4
2 Ho-PLLA-MS 52±3 nd nd nd nd
4 Ho-PLLA-MS 55±3 nd nd nd nd
6 Ho-PLLA-MS 54±5 nd nd nd nd
7 Ho-PLLA-MS 55±3 nd nd nd nd
8 Ho-PLLA-MS 58±5 nd nd nd nd
10 Ho-PLLA-MS 58±2 nd nd nd nd
Table 2 Transition tempera-
tures of Ho-PLLA-MS and
PLLA-MS (n=4–8)
nd not detectable, Tg glass tran-
sition temperature, Tc recrystal-
lization temperature, ΔHc
enthalpy of the recrystallization,
Tm melting temperature, ΔHm
enthalpy of fusion
Fig. 7 Generated amounts of radioactivity (end-of-bombardment)
plotted against ascending amounts of
166Ho-PLLA-MS following
neutron activation for 60 min. A linear relation is observed
demonstrating that no self-shielding occurs in higher amounts of
microspheres
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The strategy consisted of several techniques and calcula-
tions to determine whether the Delft nuclear reactor is
suitable for neutron activation of
165Ho-PLLA-MS. Obvi-
ously, for reasons of logistics, upscaling and flexibility, it is
important to explore whether other reactors in the world are
available, and suitable, for this purpose.
In order to screen a reactor (facility) for its suitability for
neutron activating
165Ho-PLLA-MS, it is recommended to
start with measurements of the thermal neutron flux and
calculations of the total energy deposition. The thermal
neutron flux (n/cm
2 h)/total energy deposition (MeV/g ￿ h)
ratio can then be calculated. For the Delft reactor this
r a t i oi s1 5 .T h u s ,ar a t i oo f1 5o rh i g h e ri m p l i e st h a t
166Ho-PLLA-MS of acceptable quality can expectedly be
produced. If the ratio is adequate, irradiations of a few
600 mg-samples of
165Ho-PLLA-MS are to be carried out
to assess the maximum activation time. The quality of the
166Ho-PLLA-MS ought to be evaluated by light micros-
copy and particle size analysis. If the microspheres are of
sufficient quality, SEM should be carried out. Subsequently,
the reactor conditions and variations in time are to be
investigated in more detail, viz. stability of the neutron flux.
PLLA-MS respond differently to neutron irradiation com-
pared to
165Ho-PLLA-MS, as was discussed in Section 3.1.
However, the maximally tolerable irradiation time of the two
types of microspheres was of the same order. It is therefore
suggested that initial screening of a reactor (facility) is
carried out with PLLA-MS since these particles do not
become radioactive which permits carefree handling and
analysis carried out immediately after neutron irradiation.
Apart from reactor screening and validation, some of the
methods discussed in this paper are also applicable for
quality control, which is extremely important with regard to
this highly radioactive microdevice. For instance, it is
proposed that after irradiation a small sample is evaluated
by light microscopy and/or particle size analysis.
4 Conclusions
It is concluded that
165Ho-PLLA-MS can endure neutron
activation in the Delft nuclear reactor up to 7 h and still
maintain their structural integrity. After neutron activation
for 7 h the generated activity in a typical patient dosage of
600 mg of
166Ho-PLLA-MS is high enough to allow for
sufficient time for transportation to the hospital and also high
enough to deliver liver absorbed doses in the tumoricidal
range. Furthermore, in this reactor, the two most important
reactor conditionparameters, neutron fluxand gamma heating,
are relatively constant in time, allowing for the routine
production of
166Ho-PLLA-MS of a consistent quality.
Structural integrity was preserved after at least 7 h-neutron
irradiation even though the poly(L-lactic acid) matrix of this
microdevice is in fact relatively sensitive to neutron irradia-
tion, specifically the accompanying gamma heating. DSC
measurements showed that the crystalline structure was lost
c o m p l e t e l yb e t w e e n0a n d2ho fi r r a d i a t i o n .V i s c o m e t r y
analysis also showed that chain length decreases rapidly
during neutron irradiation, yet microscopically the micro-
spheres’ surface remained virtually intact and particle size
distribution was acceptable after irradiation of 7 h.
The activated fraction was independent of the amount of
165Ho-PLLA-MS that was neutron activated, meaning no
self-shielding had occurred, at least up to the maximum
patient dosage of 1,000 mg. As expected, both spiked and
unspiked samples of
166Ho-PLLA-MS were sterile after
neutron irradiation.
Neutron flux measurements and energy deposition
calculations are required in the screening of other nuclear
reactors. For the evaluation of microsphere quality, not only
in reactor screening but also in routine quality control, light
microscopy, SEM and particle size analysis are appropriate
techniques.
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